RxDoctor Payments Data

Susan Delap, MD

Infectious Disease · Sherwood, ARNPI 1790756195

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by United Therapeutics Corporation at 34.1% of the total. Reporting peaked in 2019 at $63 and has fallen 64.6% since, to $22 in 2025. That places this record below the midpoint for infectious disease clinicians in AR, where the typical reported total is $411.

$183in general payments, 2019–2025

Across 10 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$63
  • AbbVie$52
  • Jazz Pharmaceuticals Inc.$26
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$22
  • Merck$20

What the payments were for

  • Food & beverage$183100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$183 in reported general payments places this provider in the 40th percentile of 36 infectious disease providers in Arkansas.

See all infectious disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$453,936
Medicare patients
448
Services billed
4,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin59$187,337
Vancomycin Hcl113$17,413
CeftriaxoneCeftriaxone Sodium113$13,674
Nafcillin Sodium11$10,350
ErtapenemErtapenem Sodium15$8,555
Penicillin G Potassium26$8,554
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam39$8,370
Ceftazidime17$2,355
Cefazolin Sodium40$1,454
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav78$1,409
Doxycycline Hyclate59$872
Ciprofloxacin Hcl31$570
Cephalexin41$560
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$545
Cefdinir14$532

Paid to pharmacies, not to this prescriber.

Other infectious disease in Sherwood

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →